Gala Health review

Read the asterisk before the number. Both of Gala's compounded tiers are footnoted as prices calculated on a yearly subscription plan, and the site publishes no month-to-month rate at all — the only other figure it gives is tied to a three-month plan. So the cheap monthly number that puts it near the top of a price comparison is a number you can only be charged by signing up for a year, and what a month costs on its own is something the company does not tell you. What it does have is reach: it prescribes in all fifty states, wider than most compounded-only brands manage, though it publishes no list of them. It keeps a genuine brand-name door open, at a cash price in a different league from its compounded tiers. Menopause and hormone care sit under the same roof — it is built as a women's brand — and its prices are at least on the public page rather than held back until you are inside the intake. It is injectable only, with no oral option, and it names neither the pharmacy that fills your prescription nor a single clinician.

⚠ Every compounded price is a YEARLY-subscription rate — the site footnotes both $179 and $149 with “Price calculated based on a yearly subscription plan” and publishes no month-to-month figure at all, so the cost of not committing for a year cannot be worked out before signing up

Gala GLP-1 (operated by AI Coaching, Inc., with care delivered through OpenLoop-affiliated medical groups) is built as a women's brand — its pages read “for Women” and “dosed for women's bodies” — and it runs an online intake with clinician review, LegitScript-verified, prescribing in all 50 states as a bare claim with no state list published. It carries compounded semaglutide and tirzepatide, injection only, with no oral or sublingual route yet. Its prices sit on the public page rather than behind the intake, which is worth something — but read the asterisk. Every compounded figure on the page, $179/month for all doses and $149/month for the microdose alike, is footnoted “Price calculated based on a yearly subscription plan”, and the only other number the site gives is a $199/month FAQ rate on a three-month plan. Nothing is priced by the month. There is also a real brand-name door — FDA-approved Ozempic at $1,299/month cash — and a full HRT and menopause line under the same roof.

Pricing structure

Varies by dose, plan or tier

Consult

Included in the price

Compounding pharmacy

Not publicly identified

Labs

Optional

Dietitian support

Not included

• ✓One of the lowest compounded entry points we track — $149/mo for the microdose, $179/mo for every dose — if you sign up for the year
• ✓Prescribes in all 50 states, wider reach than most compounded-only rivals
• ✓Offers a real brand-name semaglutide path (Ozempic) for people who need the FDA-approved product
• ✓Prices are published on the public page rather than held back until you are inside the quiz
• ✓Full HRT and menopause line under the same roof — it is a women's brand, so hormone and weight care are handled together

• —The cheap tiers are compounded, not the brand-name product (Wegovy/Ozempic) — matters if you're relying on insurance
• —Brand-name Ozempic through Gala is expensive (~$1,299/mo cash)
• —No oral semaglutide option yet — injectable only on the compounded track
• —Neither the compounding pharmacy (only “a wide network”) nor a single clinician is named — the credentials shown are “trained at” logos, not people

Semaglutide is a prescription medicine, and the compounded version is not the same regulated product as brand-name Wegovy or Ozempic. Whatever you decide, decide it with a clinician who knows your history — and go into that conversation with real numbers.

• Semaglutide and menopause
• Ozempic vs Wegovy
• Where compounded semaglutide stands legally
• Wegovy cost calculator
• Weight-loss projection calculator

Gala Health is one of 36 telehealth semaglutide programmes we track. The board puts every published price on one screen, ordered with the companies that pay us first — a mechanism we state there, on the page it applies to, rather than only in the small print.